2026-03-03 - TMO - Thermo Fisher Scientific Deep Dive

Article published Mar 3, 2026. Prices below use latest available snapshots.

TMO Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium-High Status: Watching — RSI 31.2, price $507.81, -1.1% this week, -10.9% 30D

Quick Snapshot

Signal	Reading
Overall	🟡 RSI 31.2 — still approaching oversold/neutral boundary. Price $507.81, -0.2% today, -1.1% this week, -10.9% 30D. SMA20 $524.67. Price -3.2% below SMA.
Moat	Wide (lab equipment, reagents, instruments monopoly)
Key insight	TMO has consolidated sideways since 02/26. Price went from $515.03 to $507.81 (-1.4% net). RSI held essentially flat at 31.2 (vs 32.2 prior) — no significant change. The SMA gap narrowed from -3.8% to -3.2%, continuing the convergence trend. The stepwise RSI recovery (5.5 → 19.2 → 32.2 → 31.2) has plateaued — consolidating near the oversold/neutral boundary. Buy action maintained — still in the entry zone.

Action Matrix

Action	Level	Why
Current	✅ Buy	RSI 31 — at oversold/neutral boundary. Wide moat. In entry zone.
Entry Zone	$490 - $525	Current $507.81 — IN ZONE
Stop-Loss	$440 (-13%)	Below multi-year support
Target	$650 (+28%)	Recovery toward SMA and prior levels

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
TMO	$507.81	-0.2%	-1.1%	-10.9%	—	-10.9%	31	🟡 Approaching Neutral	✅ Buy

Price vs Last Deep Dive (02/26)

Metric	02/26	03/03	Change
Price	$515.03	$507.81	-$7.22 (-1.4%)
RSI	32.2	31.2	-1.0 (essentially flat — consolidating)
SMA20	$535.17	$524.67	-$10.50 (SMA continuing to decline)
vs SMA	-3.8%	-3.2%	Gap continuing to narrow (but slowly)

Update from 02/26: TMO has entered a sideways consolidation phase. Price dipped slightly (-1.4%) while RSI held flat (31.2 vs 32.2). The SMA continues its sharp decline ($535 → $524.67), narrowing the gap from -3.8% to -3.2%. The convergence trend is intact but slower. The RSI recovery sequence (5.5 → 19.2 → 32.2 → 31.2) has plateaued near the oversold/neutral boundary — this is a consolidation, not a reversal. The life sciences picks-and-shovels thesis is unchanged. Buy action maintained — still in entry zone. The 30D worsened slightly from -17.8% to -10.9% as the SMA declined.

Wait — the 30D improved (less negative), not worsened. -10.9% vs -17.8% is a significant improvement from the 02/26 reading, likely base effect from one week passage.

Company Overview

One-Liner

Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, equipment, reagents, and services to every lab and pharma company globally.

Business Model

Question	Answer
What they sell	Lab instruments/equipment, scientific reagents, specialty chemicals, CRO/bioprocessing services
Who pays	Pharma/biotech (50%), hospitals/diagnostic labs (20%), academic/government (20%), industrial (10%)
Revenue model	Equipment sales (one-time), consumables/reagents (recurring), service contracts, bioproduction (recurring)
How sticky	Very high — scientific instruments require calibration, reagents are qualified per protocol, switching risks experiment reproducibility

Key Segments

Segment	Revenue %	Growth	Notes
Life Sciences Solutions	~35%	+8% YoY	Reagents, bioprocessing, gene editing tools
Analytical Instruments	~25%	+6% YoY	Mass spec, chromatography, electron microscopy
Specialty Diagnostics	~20%	+5% YoY	Clinical diagnostic kits, allergy testing
Laboratory Products & Biopharma Services	~20%	+4% YoY	Lab supplies, CRO services (PPD)

Competitive Analysis

Competitive Moat

Moat Type	Present?	Evidence
Switching costs	🟢	Scientific protocols lock in specific instruments/reagents; revalidation cost is prohibitive
Intangible assets	🟢	Thermo, Fisher Scientific, Life Technologies brand trust in research community
Network effects	🟡	Scientific literature references specific TMO instruments/reagents
Cost advantages	🟢	$45B+ revenue generates unmatched supply chain scale
Efficient scale	🟢	Only company covering full lab workflow from sample prep to analysis

Moat Width: Wide Moat Trend: Stable — life sciences R&D spend is structural, not cyclical long-term

TMO vs IQV (Comparison)

Metric	TMO (03/03)	IQV (stale 02/23)
RSI	31.2	17.4
30D	-10.9%	-32.2%
Moat	Wide	Wide
Recovery signal	Consolidating at 31	Failed recovery
Insider selling	$323.3M	-$39.8M

TMO's RSI at 31 shows consolidation; IQV at 17 shows continued distress. TMO is the better risk/reward in life sciences.

Bull Case

Why This Could Work

Essential life sciences infrastructure — Every hospital, pharma company, and lab needs TMO products. No substitution.
Bioproduction secular tailwind — mRNA, cell therapy, gene editing all require TMO's bioprocessing equipment.
RSI recovery 5.5 → 32 → 31 (consolidating) — Steady recovery, now at oversold/neutral boundary.
Picks-and-shovels for pharma AI — AI drug discovery increases demand for analytical instruments.
SMA continuing to decline toward price — Convergence continues without price needing to rise.

Upside Scenario

If This Happens	Stock Could
Bioproduction recovery + multiple normalization	$650 (+28%)
Pharma R&D spending re-acceleration	$700 (+38%)

Bear Case

What Could Go Wrong

Pharma R&D budget cuts — Largest customer segment cutting spending post-COVID boom.
Insider selling $323.3M — Among highest in our universe alongside ISRG.
China exposure — ~15% China revenue; geopolitical risk on analytical instruments.
CRO competition — PPD segment (acquired 2021) faces IQVIA competition.

Thesis Killers

Pharma top 10 companies announce R&D budget cuts exceeding 10%
China bans TMO instrument imports
Bioproduction demand collapses (mRNA era over)

Entry Strategy

Technical Levels

Level	Price	Notes
Support 1	$490	Recent floor / entry zone bottom
Support 2	$440	Stop-loss; multi-year support
Resistance 1	$524.67	SMA20 — declining toward price
Resistance 2	$580	3-month prior range
52-week high	~$627	In-window high

Entry Approach

Strategy	Details
Entry zone	$490 - $525
Starter	2% of portfolio
Add	RSI breaks above 35 with price above $520
Full	RSI > 40 + SMA20 convergence

Research Log

Date	Update
2026-02-16	Created deep dive. RSI 5.5 extreme (!). $504.82. -13% below SMA. Insider selling $323.3M. Action: Buy.
2026-02-22	Price refresh. $510.93 (+1.2%). RSI 19.2 (from 5.5 — largest improvement in coverage: +13.7 pts). SMA gap narrowed from -13% to -8.2%. Still extreme oversold. Buy maintained.
2026-02-26	Price continued recovery to $515.03 (+0.8%). RSI 19.2 → 32.2 (+13 pts — steady recovery). SMA gap narrowed from -8.2% → -3.8%. 7D +2.7%. Approaching oversold/neutral boundary. Buy maintained — near entry zone top.
2026-03-03	Sideways consolidation. Price $507.81 (-1.4% from 02/26). RSI 31.2 (essentially flat from 32.2). SMA $524.67 (continuing to decline). SMA gap: -3.2% (improving from -3.8%). 30D improved from -17.8% to -10.9%. Buy maintained — in entry zone, consolidation is healthy.

The Gold

Key Discoveries

Discovery	Implication
RSI 5.5 → 19.2 → 32.2 → 31.2 = plateau at boundary	Consolidation at oversold/neutral boundary; not a breakdown
SMA declining $556 → $535 → $524: continues toward price	Price may reach SMA without significant price move
30D improving: -17.8% → -10.9%	Base effect rolling off; 30D will continue improving
Contrasting with IQV: TMO RSI 31 vs IQV RSI 17	TMO is the better life sciences play right now

Open Questions

What drove the RSI 5.5 extreme — was it forced selling/index rebalancing?
Are the insider sales ($323.3M) on scheduled 10b5-1 plans?
What is TMO's China revenue exposure and risk?
When does TMO report next earnings?
Why is TMO recovering while IQV continues to deteriorate?

Mistakes (Don't Repeat)

Mistake	Lesson
None yet	Stepwise RSI recovery (5.5 → 19 → 32 → 31) followed by consolidation = normal base-building

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.